Three decisions cleared before this issue, and none was publicly resolved on its printed calendar date.
Bristol Myers Squibb won accelerated approval for ZENBEXUS on August 13, four days before its target. FDA accepted MRD-negative complete response as the basis for action in relapsed or refractory multiple myeloma while progression-free-survival follow-up continues.
Lantheus announced FDA approval for TAUKLARIFY on August 14, one day after the August 13 target. Whether FDA acted on August 13 or August 14 has not been publicly disclosed. The label covers brain PET imaging in cognitively impaired adults being evaluated for Alzheimer’s disease to identify tau neurofibrillary-tangle pathology, with a limitation for non-Alzheimer’s tauopathies.
ITM received a complete response letter for 177Lu-edotreotide on August 7 and disclosed it August 10—well before the former August 28 target. The cited deficiencies were CMC and inspection-related items at third-party commercial facilities, not clinical efficacy or safety.
The front of the board now moves to Capricor and Ultragenyx. CAPR’s August 22 date remains published but is expected to move after a planned amendment. RARE’s August 23 DTX401 decision is the next clean hard clock.
| Date | Sponsor / Event | Setup / Main Risk | PoA |
| SAT AUG 22* | CAPR deramiocel / DMD | Class 2 / amendment / negative AdCom Evidence / indication / timing / BIMO | 10% |
| SUN AUG 23 | RARE DTX401 / GSDIa | Priority Review BLA Endpoint / durability / CMC | 76% |
| TUE AUG 25 | JAZZ Ziihera combos / HER2+ GEA | Priority Review / RTOR Regimen / label scope | 83% |
| THU AUG 27 | GILD BIC/LEN / suppressed HIV | Priority Review NDA Resistance / regimen / label | 89% |
| SUN AUG 30 | PharmaEssentia TWSE-LISTED BESREMi / ET | Standard Review sBLA Label / safety / execution | 87% |
| THU SEP 3 | Advicenne EURONEXT-LISTED Sibnayal / dRTA | 505(b)(2) NDA U.S. bridge / CMC / label | 78% |
| FRI SEP 11 | Telix ASX-LISTED Pixclara / glioma PET | Resubmitted NDA / FT / ODD Evidence / resubmission | 75% |
* CAPR’s August 22 target remains published. Capricor says FDA will extend the review after receiving its planned amendment; the submission date, classification, extension length and new target have not been disclosed.
Board dates reflect current company and FDA disclosures. Private and non-U.S.-listed sponsors are identified by sponsor name. PoAs are PDUFA Pulse editorial estimates rounded to whole numbers.
| CAPR$CAPR · deramiocel | Aug 22* 10% |
The August 22 date remains formally in effect, but it is not a clean Saturday binary. Capricor plans to amend the BLA with 24-month open-label-extension data and additional analyses. FDA has indicated it is willing to review the amendment and will extend the action date after receipt.
The more important change is the indication. The application reviewed at the July 29 advisory committee sought treatment of cardiomyopathy in DMD. Capricor says the planned amendment will support a refined indication focused on the HOPE-3 primary endpoint—upper-limb skeletal-muscle function. The case is moving away from the cardiomyopathy proposition that received a 3–9 vote.
That shift does not eliminate the evidence dispute. FDA’s prespecified SAP 1.1 analyses were negative: the between-group difference was 0.66 points on PUL 2.0, p=0.24, and −0.04 percentage points on LVEF, nominal p=0.97. Under later analyses, Capricor reports a 4.55% PUL 2.0 difference, p=0.029, and a revised LVEF result at nominal p=0.09, versus p=0.04 previously reported. FDA classifies the later analyses as post hoc.
FDA also questions whether HOPE-3 enrolled a cardiomyopathy population at all: mean baseline LVEF was approximately 57%, and only 5 of 106 patients were below 45%. That makes the proposed shift toward upper-limb function more than a narrower label claim—it moves the case toward the population and endpoint the trial was designed to evaluate.
The primary-endpoint significance is sensitive to the handling of two placebo patients. Under SAP 3.0, FDA calculated p=0.045 with the revised imputation and censoring rules versus p=0.21 when all available data were included without that handling. FDA said the results lacked robustness to missing-data assumptions for a very small number of subjects.
The BIMO record belongs in the evidence discussion as well as execution. Capricor disclosed one Form 483 observation and says it has responded. Separately, FDA’s briefing document says its preliminary review found a deviation from the approved blinding plan: statistical programming and biostatistics moved in-house in October 2023, SAP versions 2.0 and 3.0 were prepared by the applicant, and SAP 3.0 was finalized one day before database lock and unblinding. The inspections were still ongoing when FDA prepared the document.
| GILD$GILD · bictegravir/lenacapavir | Aug 27 89% |
Gilead is seeking approval for bictegravir 75 mg plus lenacapavir 50 mg as a once-daily, two-drug single-tablet regimen for adults with HIV who are already virologically suppressed.
The package is supported by two positive noninferiority switch trials. ARTISTRY-1 is an open-label Phase 2/3 program whose Phase 3 portion evaluated patients moving from complex multi-tablet regimens. ARTISTRY-2 is a randomized, double-blind Phase 3 trial evaluating a switch from Biktarvy. Gilead reports that BIC/LEN maintained virologic suppression through Week 48 and was generally well tolerated without significant new safety concerns.
This is the cleanest remaining setup on the board, but the label still matters. FDA must define which suppressed patients can switch, how baseline resistance history is handled and whether the final language preserves the regimen’s intended simplification value.
Three actions cleared the board. None was publicly resolved on its target date.
BMY was approved four days early. ITM received its CRL 21 days before the August 28 target and disclosed it three days later. LNTH’s approval was announced August 14, the day after its August 13 target. Whether FDA acted on August 13 or August 14 has not been publicly disclosed—which is the point.
A PDUFA date tells you the review target. It does not guarantee when the sponsor will receive the letter, when the result will become public or whether the event will remain pending until that day.
Every name inside T-7 requires daily checks under the development code, active ingredient, likely brand name, sponsor newsroom and FDA databases. A calendar-only workflow will miss both early decisions and newly branded approvals.
| CAPR | Did the amended upper-limb case remain insufficient, or did BIMO, CMC or another application issue remain open? |
| RARE | Did FDA reject the cornstarch-reduction endpoint or encounter gene-therapy CMC, inspection or durability concerns? |
| JAZZ | Did FDA narrow the filing to one regimen, or did label, safety or application execution prevent approval? |
| GILD | Did resistance, population definition, regimen composition or manufacturing/label execution prevent approval? |
| PharmaEssentia TWSE | Did FDA narrow the ET population, require additional safety controls or find an execution issue in the sBLA? |
| Advicenne EURONEXT | Did the European-data bridge, 505(b)(2) basis, CMC package or proposed U.S. label fail to close? |
| Telix ASX | Did the resubmission fail to resolve FDA’s diagnostic-evidence concerns, or did label, manufacturing or distribution remain open? |
The front of the board has been rebuilt.
Resolved this cycle: BMY / ZENBEXUS, LNTH / TAUKLARIFY and ITM / 177Lu-edotreotide.
Live: CAPR* → RARE → JAZZ → GILD → PharmaEssentia → Advicenne → Telix.
Next published date: CAPR on August 22, with an extension expected after amendment receipt.
Next clean hard clock: RARE on August 23.
Highest-drama name: CAPR. The live questions now include the evidence, the proposed indication and the clock itself.
Cleanest setup: GILD. Two positive Phase 3 noninferiority switch studies support the once-daily BIC/LEN regimen; label scope and execution are the main residual questions.
Informational only · Not investment advice · Biotech carries risk of total loss